HHV-6 DNA and RNA Qualitative Detection Test in UAE | 650 AED | DHA Licensed

Executive Summary & Core Metrics

This molecular assay delivers definitive qualitative detection of Human Herpesvirus 6 (HHV-6) DNA and RNA via validated real-time PCR technology, enabling precise discrimination between latent infection and active viral reactivation. The test is processed in ISO 9001:2015 accredited laboratories (Cert: INT/EGQ/2509DA/3139) under rigorous quality management systems approved by the Dubai Health Authority.

✅99.9% Diagnostic Sensitivity – Dual-target nucleic acid amplification eliminates serological window-period ambiguity.
🏥Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety.
📞Post-Test Clinical Guidance – Telephonic result interpretation provided by a DHA-licensed physician within 24 hours of report release.
📋Insurance Direct Billing Verification – Submit via WhatsApp +971 54 548 8731 for real-time coverage confirmation.

Test Overview & Methodology

This qualitative PCR test simultaneously detects Human Herpesvirus 6 (HHV-6) DNA and RNA across multiple specimen matrices including saliva, whole blood, cerebrospinal fluid (CSF), lymph node tissue, and biopsy samples. By targeting both viral genomic material and transcribed RNA, the assay provides unambiguous evidence of active viral replication, making it indispensable for managing immunocompromised patients, transplant recipients, and individuals with suspected central nervous system infections. The dual-target strategy overcomes the inherent limitations of serology, which cannot differentiate past exposure from current infection.

Feature	Our Test (qPCR + RNA)	Conventional Serology (IgG/IgM)
Detection Target	Viral DNA + RNA (direct pathogen detection)	Host antibody response (indirect)
Methodology	Real-Time PCR with simultaneous reverse transcription	ELISA / Immunofluorescence Assay
Turnaround Time	24–36 hours (preliminary RNA result at 24 h)	48–72 hours
Clinical Sensitivity	99.9%	~70–80% (window-period false negatives)
Ideal Clinical Context	Immunocompromised, transplant, CNS infection, early reactivation	Retrospective immunity screening, seroprevalence studies

Physician Insight & Safety Protocols

"In my clinical experience, HHV-6 nucleic acid testing is indispensable for immunocompromised patients presenting with unexplained febrile illness or neurological deterioration. This PCR-based assay removes the diagnostic uncertainty inherent in serology, particularly for transplant recipients where viral reactivation can mimic graft-versus-host disease. I strongly advise patients to share this result with their treating specialist for full clinical integration—never interpret a positive finding in isolation."

— Dr. Ajay Singh, General Practitioner | DHA Registration ID: 36234132

Medication Advisory

⚠️ Critical Notice – Do Not Self-Adjust Therapy

Do not discontinue, reduce, or alter any prescribed antiviral, immunosuppressive, or immunomodulatory medication without explicit consultation with your doctor. Abrupt changes in therapy can trigger viral rebound, acute graft rejection, or dangerous disease exacerbation. Always present your PCR result to the prescribing clinician before making any treatment decision.

Safety Exclusion Criteria & Emergency Red Flags

Criteria for Safe Sample Collection

🚫Exclusion – Inadequate Sample Access: Inability to obtain sufficient specimen volume (e.g., severe dehydration contraindicating venipuncture, or anatomical contraindication to lumbar puncture for CSF collection).
🚫Exclusion – Bleeding Risk: Known coagulopathy or active anticoagulant therapy that cannot be temporarily withheld under medical supervision for invasive procedures.
🚨Emergency Red Flag – Neurological Deterioration: If you experience new-onset seizures, altered consciousness, severe headache, nuchal rigidity, or focal neurological deficits—seek emergency care immediately without waiting for test results.
🚨Emergency Red Flag – Systemic Instability: New fever accompanied by respiratory distress, hypotension, or acute confusion requires urgent clinical evaluation regardless of PCR status.

Patient FAQ & Clinical Guidance

1. What does a positive HHV-6 DNA result mean for my health?

A positive HHV-6 DNA result indicates active viral replication within your body. This finding must be interpreted in the context of your immune status, clinical symptoms, and organ function. In immunocompromised individuals, it may signify reactivation requiring immediate antiviral intervention, whereas in healthy hosts it could represent transient shedding. Always discuss the result with your specialist for a personalized treatment plan.

2. How is the sample collected and what level of discomfort should I expect?

Collection depends on the specimen type prescribed by your physician. Venipuncture for whole blood causes mild transient discomfort; saliva self-collection is entirely painless; CSF collection via lumbar puncture is performed under local anesthesia by a trained specialist in a hospital setting. For all invasive procedures, a detailed informed consent is obtained beforehand.

3. When will I receive my results and is expedited processing available?

Routine results are delivered via encrypted email by the third working day. A premium fast-track service provides preliminary RNA detection within 24 hours from sample receipt, provided the specimen reaches the laboratory before 2 PM. Contact our patient coordination team via WhatsApp +971 54 548 8731 to activate priority processing.

4. Can this test differentiate between HHV-6A and HHV-6B subtypes?

Yes. Our validated PCR assay includes subtype-specific probes that distinguish HHV-6A (more commonly associated with neurological involvement) from HHV-6B (predominant in transplant populations). Subtype identification is included in the standard report at no additional charge and aids in targeted therapeutic decision-making.

UAE Regulatory & Data Privacy Adherence

Legal & Compliance Framework

This diagnostic service fully complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All patient data is encrypted in transit and at rest, processed in ISO 9001:2015 certified facilities, and accessible only to authorized clinical personnel. Clinical safety and patient consent protocols adhere strictly to Federal Decree-Law No. 4 of 2016 on Medical Liability. Direct billing verification and result delivery operate under the Dubai Health Authority regulatory framework for licensed diagnostic laboratories.

Clinical & Logistical Metadata

Test Name	HHV-6 DNA and RNA Qualitative Detection (Real-Time PCR)
Price (AED)	650 AED
Turnaround Time	24–36 hours (preliminary RNA report at 24 h)
Sample Type / Matrix	Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety.
Methodology Used	Real-Time PCR with reverse transcription (RT-qPCR) plus optional subtype genotyping
ICD-10-CM Code	B10.89, B10.81
LOINC Code	7754-9
DHA Facility License & Address	DHA Facility License Number: 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE \| DNA Labs UAE

دعم ثنائي اللغة متاح

التحقق من التغطية التأمينية

Check Insurance Coverage Instantly

Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.

توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.

✅ DHA Certified ✅ ISO 15189 ✅ HIPAA Compliant

💬 التحقق عبر الواتساب Verify via WhatsApp 📞 Call Team

Available in Arabic, English, Hindi & Urdu

🏅

ISMS 27001:2022

📋

ISO Accredited

🔒

HIPAA

All reports reviewed by DHA-Certified physicians